By Decree of the Government of the Russian Federation No. 1392 dated September 10, 2025, amendments were made to Resolution No. 719 dated July 17, 2015, regulating the confirmation of the production of industrial products in Russia. The changes came into force on July 1, 2026 and relate to pharmaceutical products.
It has been established that pharmaceutical products included in section VIII of the annex to Resolution No. 719 can be classified as Russian industrial products, provided they achieve at least 50 points for the implementation of technological processes in the territories of the EAEU states for each unit of industrial products.
The localization confirmation point system is not a new tool in itself: a similar mechanism has long been used for other industries, from automotive to electronics. For pharmaceuticals, the threshold of 50 points has now been formalized separately, with reference specifically to technological operations performed on the territory of the EAEU, and not only to the country of registration of the legal entity or the place of packaging of finished products.
The status of Russian industrial products is not a formality. Access to preferences for participation in public procurement depends on it, where price and quota preferences apply to localized products, as well as the opportunity to work with large customers for whom having such a status with a supplier is a prerequisite for a contract.
Manufacturers of pharmaceutical products subject to section VIII of Resolution No. 719 should conduct an independent audit of the technological chain: determine which operations are performed on the territory of the EAEU and which are performed outside it, and calculate the final score according to the current accrual methodology. If the actual result is close to or below the threshold, it makes sense to consider moving some operations to sites within the Union before the lack of status affects participation in tenders.
